Title:
A multicenter open-label phase 1 study evaluating the safety and tolerability of HMPL-306 in patients with locally advanced or metastatic solid tumors with IDH mutations.
Lead Author
Session:
Abstract Number:
About Savolitinib
Savolitinib is an oral, potent, and highly selective small molecule inhibitor of MET, a receptor tyrosine kinase which has been shown to function abnormally in many types of solid tumors promoting tumor growth, angiogenesis, and metastasis. Savolitinib has been studied in over 1,100 patients to date. In clinical studies, it has shown promising clinical efficacy in patients with MET gene alterations in multiple tumor types with an acceptable safety profile.
HUTCHMED Highlights Clinical Data to be Presented at the Upcoming ASCO21 Virtual Scientific Program
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
HUTCHMED Highlights Clinical Data to be Presented at the Upcoming ASCO21 Virtual Scientific Program
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
Investegate |Hutchmed China Ltd Announcements | Hutchmed China Ltd: Clinical Data to be Presented at ASCO21
investegate.co.uk - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from investegate.co.uk Daily Mail and Mail on Sunday newspapers.
Health brief: Whitecar honored by National Cancer Research Association
By Special to The Dispatch 7 hours ago
John P. Whitecar
COLUMBUS Columbus oncologist Dr. John P. Whitecar, Jr. has been recognized for his 50 years of dedication to cancer research and membership in the American Association for Cancer Research (AACR).
The AACR is the world’s oldest and largest professional association related to cancer research. Based in Philadelphia, the AACR focuses on all aspects of cancer research, including basic, clinical, and translational research into the etiology, prevention, diagnosis, and treatment of cancer.
Whitecar was one of 32 members of the association who were inducted into the 50-year member ranks during the association’s annual meeting in early April. He is currently in practice at Baptist Cancer Center – Golden Triangle and he has been on staff at Baptist Memorial Hospital – Golden Triangle since 1997.